A Study of TAK-861 for the Treatment of Selected Central Hypersomnia Conditions (NCT05816382)
A Long-term Extension Study to Evaluate the Safety and Tolerability of TAK-861 in Participants With Selected Central Hypersomnia Conditions
🩺 Plain-English Summary (8th-Grade Level)
The main aim is to evaluate the safety and tolerability of TAK-861 in participants with type 1 narcolepsy, who were exposed to previously tested doses of TAK-861.
Who can join: Review the eligibility criteria below.
Location: Sleep Disorders Center of Alabama — Birmingham, Alabama
Age range: 16 Years to 70 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (52 Sites)
Showing the first 25 of 52 sites.
- Sleep Disorders Center of Alabama — Birmingham, Alabama
- Stanford Center for Sleep Sciences and Medicine — Redwood City, California
- SDS Clinical Trials, Inc. — Santa Ana, California
- Delta Waves LLC - Hunt - PPDS — Colorado Springs, Colorado
- Florida Pediatric Research Institute — Orlando, Florida
- Neurotrials Research — Atlanta, Georgia
- Georgia Neuro Center — Gainesville, Georgia
- Neurocare Inc — Newton, Massachusetts
- Henry Ford Medical Center - Columbus — Novi, Michigan
- Research Carolina Elite — Denver, North Carolina
- ARSM Research, LLC — Huntersville, North Carolina
- CTI Research Center — Cincinnati, Ohio
- Intrepid Research — Cincinnati, Ohio
- The Cleveland Clinic Foundation — Cleveland, Ohio
- Ohio Sleep Medicine Institute — Dublin, Ohio
- Medical University of South Carolina - PPDS — Charleston, South Carolina
- Bogan Sleep Consultants, LLC — Columbia, South Carolina
- Sleep Therapy and Research Center — San Antonio, Texas
- Children's Specialty Group — Norfolk, Virginia
- Woolcock Institute of Medical Research — Glebe, New South Wales
- Terveystalo Helsinki Sleep Clinic — Helsinki, Uusimaa
- Hopital Pierre-Paul Riquet — Toulouse, Haute-Garonne
- CHU Gui De Chauliac — Montpellier, Herault
- CHU de Grenoble — La Tronche, Isere
- Hopital de la Pitie Salpetriere — Paris,
📞 Contact the Study Coordinator
Phone: (877) 825-3327
Email: medinfoUS@takeda.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Narcolepsy Type 1
- A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic Hypersomnia — Cullman, Alabama
- A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1 — Cullman, Alabama
- A Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia — Auburn, Alabama
- A Long-term Extension Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia — Auburn, Alabama
- A Study to Evaluate the Efficacy, Safety and Tolerability of ALKS 2680 in Adults With Narcolepsy Type 1 (Brilliance NT1 - 304) — Miami, Florida
- A Study to Investigate the Effects of Cleminorexton Compared With Placebo in the Treatment of Participants With Central Disorders of Hypersomnolence — Colorado Springs, Colorado
Explore by condition: All Narcolepsy Type 1 clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.